<DOC>
	<DOCNO>NCT00062244</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose oblimersen see well work treat patient relapsed refractory Waldenstrom 's macroglobulinemia . Biological therapy oblimersen may interfere growth cancer cell slow stop growth Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Oblimersen Treating Patients With Relapsed Refractory Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose ( MTD ) recommend dose Genasense patient relapse refractory WM follow prior chemotherapy . ( Phase I ) II . To determine response rate Genasense patient relapse refractory WM follow prior chemotherapy . III . To determine safety Genasense patient relapse refractory WM follow prior chemotherapy . IV . To describe possible clinical benefit Genasense treatment relapse refractory WM include duration response , survival , erythropoietin use , improvement hemoglobin &gt; 11 g/dl , Improvement platelet count &gt; 100,000/mm^3 . OUTLINE : This multicenter , dose-escalation study . Phase I : Patients receive oblimersen IV continuously day 1-7 . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos oblimersen maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Phase II : Patients receive treatment phase I MTD oblimersen . Patients follow every 3 month 2 year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Diagnosis Waldenstrom 's macroglobulinemia ( WM ) confirm follow : Bone marrow lymphoplasmacytosis great 10 % lymphoplasmacytic cell aggregate , sheet , lymphocyte , plasma cell , lymphoplasmacytic cell bone marrow biopsy Measurable disease , define quantitative IgM monoclonal protein great 1,000 mg/dL Symptomatic relapse refractory disease require therapy , define least 1 follow : Impaired bone marrow function due disease infiltration demonstrate follow : Hemoglobin le 11 g/dL Requires epoetin alfa therapy maintain hemoglobin least 11 g/dL Platelet count le 100,000/mm^3 Symptomatic bulky lymphadenopathy Symptoms attributable hyperviscosity ( e.g. , nose bleeding , gingival bleeding , retinal hemorrhage ) serum viscosity level relative water great 4 Received least 1 prior chemotherapy regimen include chlorambucil , cyclophosphamide , fludarabine , cladribine , pentostatin No secondary leukemia history antecedent hematologic disorder ( e.g. , myelodysplasia ) prior initial onset WM Performance status ECOG 02 Not specify See Disease Characteristics Absolute neutrophil count least 1,000/mm^3* Platelet count least 50,000/mm^3* No bleed disorder Bilirubin great 2 time upper limit normal ( ULN ) AST le 1.5 time ULN Albumin least 2.5 g/dL PT great 1.5 time ULN INR great 1.3 PTT great 1.5 time ULN No history chronic hepatitis cirrhosis Creatinine great 2 time ULN No uncontrolled congestive heart failure No active symptom coronary artery disease , include follow : Uncontrolled arrhythmias Recurrent chest pain despite prophylactic medication No New York Heart Association class III IV heart disease No grade 2 great cardiovascular sign symptom within past 4 week HIV negative Direct Coombs ' test negative No autoimmune thrombocytopenia No uncontrolled serious infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Adequate venous access 7day continuous infusion study drug Intellectual , emotional , physical ability maintain ambulatory infusion pump No cancer except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , cancer patient diseasefree least 5 year No know hypersensitivity phosphorothioatecontaining oligonucleotides No uncontrolled seizure disorder More 21 day since prior immunotherapy WM More 21 day since prior cytokine , biologic , vaccine therapy WM More 8 week since prior plasmapheresis plasma exchange No prior allogeneic stem cell transplantation No concurrent plasmapheresis plasma exchange See Disease Characteristics No concurrent corticosteroid therapy More 21 day since prior radiotherapy WM More 21 day since prior major surgery WM No prior organ allograft Recovered prior therapy More 21 day since prior therapy WM No concurrent investigational therapy No concurrent immunosuppressive drug No concurrent therapeutic anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>